|
๐
|
Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis
7 auth.
G. Maglietta,
F. Diodati,
M. Puntoni,
S. Lazzarelli,
B. Marcomini,
L. Patrizi,
...
C. Caminiti
|
6 |
2022 |
6
๐
|
|
๐
|
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
30 auth.
A. Ruzzo,
Francesco Graziano,
F. Galli,
F. Galli,
E. Rulli,
S. Lonardi,
M. Ronzoni,
Bruno Massidda,
V. Zagonel,
N. Pella,
C. Mucciarini,
R. Labianca,
M. Ionta,
I. Bagaloni,
E. Veltri,
...
P. Sozzi,
S. Barni,
V. Ricci,
L. Foltran,
Mario Nicolini,
Edoardo Biondi,
A. Bramati,
Daniele Turci,
S. Lazzarelli,
C. Verusio,
F. Bergamo,
A. Sobrero,
L. Frontini,
M. Menghi,
Mauro Magnani
|
5 |
2017 |
5
๐
|
|
๐
|
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
30 auth.
A. Ruzzo,
F. Graziano,
F. Galli,
E. Giacomini,
I. Floriani,
F. Galli,
E. Rulli,
S. Lonardi,
M. Ronzoni,
B. Massidda,
V. Zagonel,
N. Pella,
C. Mucciarini,
R. Labianca,
M. Ionta,
...
E. Veltri,
P. Sozzi,
S. Barni,
V. Ricci,
L. Foltran,
M. Nicolini,
E. Biondi,
A. Bramati,
D. Turci,
S. Lazzarelli,
C. Verusio,
F. Bergamo,
A. Sobrero,
L. Frontini,
M. Magnani
|
5 |
2014 |
5
๐
|
|
๐
|
The Effects of Patient-Reported Outcome Screening on the Survival of People with Cancer: A Systematic Review and Meta-Analysis
8 auth.
C. Caminiti,
G. Maglietta,
F. Diodati,
M. Puntoni,
B. Marcomini,
S. Lazzarelli,
...
C. Pinto,
F. Perrone
|
4 |
2022 |
4
๐
|
|
๐ฌ
|
A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.
S. Buti,
M. Donini,
S. Lazzarelli,
R. Passalacqua
|
3 |
2012 |
3
๐ฌ
|
|
๐
|
Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
7 auth.
M. Bersanelli,
S. Buti,
R. Camisa,
M. Brighenti,
S. Lazzarelli,
G. Mazza,
...
R. Passalacqua
|
3 |
2014 |
3
๐
|
|
๐
|
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
29 auth.
A. Ruzzo,
F. Graziano,
F. Galli,
F. Galli,
E. Rulli,
S. Lonardi,
M. Ronzoni,
B. Massidda,
V. Zagonel,
N. Pella,
C. Mucciarini,
R. Labianca,
M. Ionta,
I. Bagaloni,
E. Veltri,
...
P. Sozzi,
S. Barni,
V. Ricci,
L. Foltran,
M. Nicolini,
E. Biondi,
A. Bramati,
D. Turci,
S. Lazzarelli,
C. Verusio,
F. Bergamo,
A. Sobrero,
L. Frontini,
M. Magnani
|
3 |
2019 |
3
๐
|
|
๐
|
Final Results of the Randomized Phase II NorCapโCA223 Trial Comparing FirstโLine AllโOral Versus TaxaneโBased Chemotherapy for HER2โNegative Metastatic Breast Cancer
12 auth.
S. Cinieri,
A. Chan,
K. Altundaฤ,
A. Vandebroek,
N. Tubiana-Mathieu,
A. Barnadas,
...
P. Dodyk,
S. Lazzarelli,
Michiel Botha,
D. Rauch,
G. Villanova,
U. Coลkun
|
3 |
2017 |
3
๐
|
